News
ALEC
1.990
+9.94%
0.180
Alector surges on licensing agreement with Genentech
Seeking Alpha · 18h ago
Analysts Conflicted on These Healthcare Names: Capricor Therapeutics (CAPR), Alector (ALEC) and Irhythm Technologies (IRTC)
TipRanks · 18h ago
Why is Alector Stock (ALEC) 60% Higher Today?
TipRanks · 19h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 21h ago
Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy
Dow Jones · 21h ago
Alector Signs Global License Deal With Genentech For AL050
NASDAQ · 21h ago
Alector Licenses AL050 GCase Program to Genentech
TipRanks · 21h ago
Alector enters exclusive AL050 global licensing agreement with Genentech
TipRanks · 21h ago
Alector Teams Up With Genentech On Potential Parkinson’s Treatment
Benzinga · 22h ago
Weekly Report: what happened at ALEC last week (0928-1002)?
Weekly Report · 23h ago
Weekly Report: what happened at ALEC last week (0921-0925)?
Weekly Report · 09/28 09:13
Weekly Report: what happened at ALEC last week (0914-0918)?
Weekly Report · 09/21 09:14
Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint
NASDAQ · 09/17 09:00
Weekly Report: what happened at ALEC last week (0907-0911)?
Weekly Report · 09/14 09:14
Weekly Report: what happened at ALEC last week (0831-0904)?
Weekly Report · 09/07 09:13
Don't Ignore The Insider Selling In Alector
Simply Wall St · 09/06 12:04
Top Alector Executives Quietly Unload a Wave of Shares
TipRanks · 09/05 02:05
Weekly Report: what happened at ALEC last week (0824-0828)?
Weekly Report · 08/31 09:14
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/25 21:06
Weekly Report: what happened at ALEC last week (0817-0821)?
Weekly Report · 08/24 09:15
More
Webull provides a variety of real-time ALEC stock news. You can receive the latest news about Alector through multiple platforms. This information may help you make smarter investment decisions.
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.